Poonam Sahu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Poonam Sahu has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Trilochan Satapathy
Columbia Institute of Pharmacy, Raipur, 493111, Chhattisgarh, India
28 shared publications - Abhisek Satapathy
Pt J.N.M. Medical College, Railway Station Rd, Moudhapara, Raipur, 492001, C.G., India
15 shared publications - Abinash Satapathy
College of Veterinary Science and Animal Husbandry, Anjora, Durg, 491001, C.G, India
11 shared publications Trilochan Satapathy
7 shared publications- Shiv Kumar Bhardwaj
Columbia Institute of Pharmacy, Columbia Professional University, Tekari, Near Vidhansabha Road, Raipur-493111, Chhattisgarh, India
6 shared publications - Kamlesh Sahu
Columbia Institute of Pharmacy, Vill-Tekari, Near Vidhansabha, Raipur, 493111, C.G., India
5 shared publications
Latest Publications
- Open Access
- 1 December 2026
- Published by KEAI Publishing in Nano TransMed
- Vol. 5
Nanotechnology-enhanced liquid biopsies and genomic biomarkers: Emerging landscapes for early cancer detection
- 1 December 2026
- Published by KEAI Publishing in Nano TransMed
- Vol. 5
Open AccessNanotechnology-enhanced liquid biopsies and genomic biomarkers: Emerging landscapes for early cancer detection
- 11 October 2026
- Published by Springer Nature in Apoptosis
- Vol. 31  (11) , 245
Nano-engineered phytochemicals in cancer therapy: mechanistic insights into apoptosis, ferroptosis, tumor microenvironment modulation and drug resistance reversal
Cancer progression and therapeutic resistance are driven by interconnected mechanisms involving redox imbalance, metabolic plasticity, epigenetic remodeling and tumor microenvironment (TME)-mediated immune suppression. Conventional “one drug-one target” therapies often fail to overcome these adaptive oncogenic networks, resulting in multidrug resistance and disease relapse. This review aims to explore the therapeutic potential of nano-engineered phytochemicals in cancer management, with emphasis on ferroptosis induction, oncogenic pathway modulation and TME reprogramming for overcoming tumor resistance. A comprehensive narrative review was conducted focusing on recent advances in nano-phytomedicine, ferroptosis-based anticancer strategies and precision nanotherapeutic approaches. Relevant literature was systematically collected from PubMed, Scopus, ScienceDirect and Web of Science databases, considering both preclinical and clinical studies. Retrieved studies were critically analyzed to evaluate the therapeutic effects of nano-engineered phytochemicals on major oncogenic signaling pathways, including PI3K/Akt, NF-κB, STAT3, HIF-1α and NRF2. Mechanistic evidence associated with ferroptosis induction, reactive oxygen species (ROS) modulation, oxidative stress regulation, immune reprogramming and tumor microenvironment (TME) remodeling was systematically assessed. Preclinical studies indicate that nano-engineered phytochemicals can modulate interconnected oncogenic, metabolic, redox and immune pathways and can improve physicochemical and pharmacokinetic properties relative to free phytochemicals. Ferroptosis-associated effects include modulation of glutathione metabolism, GPX4, SLC7A11, iron homeostasis and lipid peroxidation; however, these molecular changes do not independently establish ferroptotic cell death. Evidence for tumour-microenvironment modulation and multidrug-resistance reversal remains predominantly preclinical, whereas human studies are limited and mainly address pharmacokinetic, tolerability or early efficacy outcomes. Nano-engineered phytochemicals represent a promising systems-oriented therapeutic strategy, but their clinical potential remains incompletely established. Future development requires rigorous mechanistic validation, reproducible formulation and manufacturing processes, biomarker-guided clinical evaluation, and comprehensive assessment of biodistribution, toxicity and long-term safety. Clinical trial: The manuscript is a review article (not a part of Clinical trial), hence no Clinical trial no is applicable.
- 11 October 2026
- Published by Springer Nature in Apoptosis
- Vol. 31  (11) , 245
Nano-engineered phytochemicals in cancer therapy: mechanistic insights into apoptosis, ferroptosis, tumor microenvironment modulation and drug resistance reversal
Cancer progression and therapeutic resistance are driven by interconnected mechanisms involving redox imbalance, metabolic plasticity, epigenetic remodeling and tumor microenvironment (TME)-mediated immune suppression. Conventional “one drug-one target” therapies often fail to overcome these adaptive oncogenic networks, resulting in multidrug resistance and disease relapse. This review aims to explore the therapeutic potential of nano-engineered phytochemicals in cancer management, with emphasis on ferroptosis induction, oncogenic pathway modulation and TME reprogramming for overcoming tumor resistance. A comprehensive narrative review was conducted focusing on recent advances in nano-phytomedicine, ferroptosis-based anticancer strategies and precision nanotherapeutic approaches. Relevant literature was systematically collected from PubMed, Scopus, ScienceDirect and Web of Science databases, considering both preclinical and clinical studies. Retrieved studies were critically analyzed to evaluate the therapeutic effects of nano-engineered phytochemicals on major oncogenic signaling pathways, including PI3K/Akt, NF-κB, STAT3, HIF-1α and NRF2. Mechanistic evidence associated with ferroptosis induction, reactive oxygen species (ROS) modulation, oxidative stress regulation, immune reprogramming and tumor microenvironment (TME) remodeling was systematically assessed. Preclinical studies indicate that nano-engineered phytochemicals can modulate interconnected oncogenic, metabolic, redox and immune pathways and can improve physicochemical and pharmacokinetic properties relative to free phytochemicals. Ferroptosis-associated effects include modulation of glutathione metabolism, GPX4, SLC7A11, iron homeostasis and lipid peroxidation; however, these molecular changes do not independently establish ferroptotic cell death. Evidence for tumour-microenvironment modulation and multidrug-resistance reversal remains predominantly preclinical, whereas human studies are limited and mainly address pharmacokinetic, tolerability or early efficacy outcomes. Nano-engineered phytochemicals represent a promising systems-oriented therapeutic strategy, but their clinical potential remains incompletely established. Future development requires rigorous mechanistic validation, reproducible formulation and manufacturing processes, biomarker-guided clinical evaluation, and comprehensive assessment of biodistribution, toxicity and long-term safety. Clinical trial: The manuscript is a review article (not a part of Clinical trial), hence no Clinical trial no is applicable.
- 24 September 2026
- Published by Bentham Science Publishers Ltd. in Drug Delivery Letters
- Vol. 16, 1-41
Quantum-Engineered Polymeric Nanonetworks for Receptor-Targeted Drug Delivery: Molecular Determinants of Signaling Modulation and PK/PD Optimization
Introduction/Objective: Quantum-Engineered Polymeric Nanonetworks (QEPNs) represent an emerging platform for targeted drug delivery that integrates polymer nanostructure engineering with quantum-scale electronic modulation. By exploiting phenomena such as quantum confinement and coherence-driven charge redistribution, QEPNs may regulate ligand-receptor interactions, enhance targeting precision, and improve therapeutic selectivity. This study aimed to describe the design principles and therapeutic potential of QEPNs for receptor-targeted drug delivery and signaling modulation. Methods: QEPNs were rationally designed through controlled modulation of polymer backbone conjugation, crosslink density, and network topology to optimize electronic coupling and multivalent receptor engagement. Quantum-informed Pharmacokinetic/Pharmacodynamic (PK/PD) modeling was employed to investigate cooperative binding mechanisms, receptor residence time, association kinetics, and nonlinear dose-response relationships associated with nanonetwork-mediated signaling modulation. Results: The engineered QEPNs demonstrated enhanced receptor-binding stability, prolonged receptor engagement, and improved selectivity toward tissues exhibiting receptor overexpression. These properties were associated with increased cellular uptake, sustained signaling activity, and controlled drug-release profiles, while reducing potential off-target interactions. Furthermore, quantum-informed PK/PD analysis indicated improved association kinetics and enhanced therapeutic efficiency at reduced drug concentrations, supporting the potential of QEPNs for precision drug delivery. Discussion: The findings suggest that integrating quantum-engineering principles with polymeric nanonetwork architecture may provide additional control over receptor recognition, cellular uptake, and drug-release behavior. The combination of multivalent receptor engagement and quantum-informed PK/PD modeling may enable more precise modulation of therapeutic exposure and signaling responses than conventional polymeric delivery systems. However, these proposed advantages require systematic experimental validation, particularly regarding the relationship between quantum-scale physicochemical properties, biological interactions, pharmacokinetics, and therapeutic outcomes. Conclusion: QEPNs provide a potentially transformative framework for precision drug delivery by integrating quantum engineering with polymer-based nanotherapeutic systems. Their ability to modulate receptor interactions, cellular uptake, and drug-release characteristics may improve therapeutic selectivity and efficiency. Further studies addressing long-term safety, biological validation, scalable manufacturing, reproducibility, and regulatory requirements are essential to determine their translational potential.
- 24 September 2026
- Published by Bentham Science Publishers Ltd. in Drug Delivery Letters
- Vol. 16, 1-41
Quantum-Engineered Polymeric Nanonetworks for Receptor-Targeted Drug Delivery: Molecular Determinants of Signaling Modulation and PK/PD Optimization
Introduction/Objective: Quantum-Engineered Polymeric Nanonetworks (QEPNs) represent an emerging platform for targeted drug delivery that integrates polymer nanostructure engineering with quantum-scale electronic modulation. By exploiting phenomena such as quantum confinement and coherence-driven charge redistribution, QEPNs may regulate ligand-receptor interactions, enhance targeting precision, and improve therapeutic selectivity. This study aimed to describe the design principles and therapeutic potential of QEPNs for receptor-targeted drug delivery and signaling modulation. Methods: QEPNs were rationally designed through controlled modulation of polymer backbone conjugation, crosslink density, and network topology to optimize electronic coupling and multivalent receptor engagement. Quantum-informed Pharmacokinetic/Pharmacodynamic (PK/PD) modeling was employed to investigate cooperative binding mechanisms, receptor residence time, association kinetics, and nonlinear dose-response relationships associated with nanonetwork-mediated signaling modulation. Results: The engineered QEPNs demonstrated enhanced receptor-binding stability, prolonged receptor engagement, and improved selectivity toward tissues exhibiting receptor overexpression. These properties were associated with increased cellular uptake, sustained signaling activity, and controlled drug-release profiles, while reducing potential off-target interactions. Furthermore, quantum-informed PK/PD analysis indicated improved association kinetics and enhanced therapeutic efficiency at reduced drug concentrations, supporting the potential of QEPNs for precision drug delivery. Discussion: The findings suggest that integrating quantum-engineering principles with polymeric nanonetwork architecture may provide additional control over receptor recognition, cellular uptake, and drug-release behavior. The combination of multivalent receptor engagement and quantum-informed PK/PD modeling may enable more precise modulation of therapeutic exposure and signaling responses than conventional polymeric delivery systems. However, these proposed advantages require systematic experimental validation, particularly regarding the relationship between quantum-scale physicochemical properties, biological interactions, pharmacokinetics, and therapeutic outcomes. Conclusion: QEPNs provide a potentially transformative framework for precision drug delivery by integrating quantum engineering with polymer-based nanotherapeutic systems. Their ability to modulate receptor interactions, cellular uptake, and drug-release characteristics may improve therapeutic selectivity and efficiency. Further studies addressing long-term safety, biological validation, scalable manufacturing, reproducibility, and regulatory requirements are essential to determine their translational potential.
- Open Access
- 18 September 2026
- Published by Elsevier in Biomaterials and Living Medicine for Pharmaceutics
- Vol. 1
Multifunctional biomaterial nanocarriers for gene-chemotherapeutic co-delivery: molecular mechanisms, design strategies and clinical translation in precision cancer therapy
- 18 September 2026
- Published by Elsevier in Biomaterials and Living Medicine for Pharmaceutics
- Vol. 1
Open AccessMultifunctional biomaterial nanocarriers for gene-chemotherapeutic co-delivery: molecular mechanisms, design strategies and clinical translation in precision cancer therapy
- 28 August 2026
- Published by Bentham Science Publishers Ltd. in Glucolipid Metabolic Disorders
- Vol. 01  (1) , 75-91
From Soybean Oil to Signaling Molecules: Oxylipins as Pharmacologically Active Lipids Modulating Liver and Metabolic Health
Introduction: Glucolipid metabolic disorders, including Metabolic Dysfunction- Associated Steatotic Liver Disease (MASLD), formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD), insulin resistance, Type 2 Diabetes Mellitus (T2DM) and obesity, are characterized by dysregulated hepatic lipid metabolism, impaired glucose homeostasis and systemic energy imbalance. Oxylipins, a diverse class of oxygenated bioactive metabolites derived from Polyunsaturated Fatty Acids (PUFAs), have emerged as key lipid mediators that link dietary fatty acid composition to intracellular metabolic signaling pathways. Soybean oil, a major dietary source of linoleic acid and α-linolenic acid, provides abundant substrates for oxylipin biosynthesis via cyclooxygenase (COX), lipoxygenase (LOX), cytochrome P450 (CYP), and non-enzymatic oxidative pathways. This review comprehensively examines the mechanistic roles of soybean oil-derived oxylipins in regulating hepatic glucolipid metabolism and highlights their potential as therapeutic targets and diagnostic biomarkers for glucolipid metabolic disorders. Methods: Relevant peer-reviewed studies were identified through a comprehensive review of experimental, clinical, and lipidomics-based literature. Evidence related to oxylipin biosynthesis, receptormediated signaling, metabolic regulation, oxidative stress, inflammation, and glucolipid metabolic disorders was critically evaluated and systematically synthesized to provide an integrated mechanistic framework and highlight the therapeutic and diagnostic potential of oxylipins in metabolic diseases. Results: Current evidence indicates that oxylipins play pivotal roles in regulating glucolipid metabolism by activating G protein-coupled receptors and nuclear receptors, including Peroxisome Proliferator- Activated Receptor-α (PPARα), Peroxisome Proliferator-Activated Receptor-γ (PPARγ) and Liver X Receptors (LXRs). Through these signaling pathways, oxylipins regulate fatty acid oxidation, de novo lipogenesis, gluconeogenesis and insulin signaling, thereby maintaining metabolic homeostasis. Linoleic acid-derived oxylipins are generally associated with enhanced oxidative stress, mitochondrial dysfunction, chronic inflammation and insulin resistance. In contrast, cytochrome P450 (CYP)-derived epoxy-fatty acids exhibit anti-inflammatory, antioxidant and insulin-sensitizing properties that promote hepatic metabolic homeostasis. Moreover, disease-specific alterations in oxylipin profiles are strongly associated with hepatic lipid accumulation, lipid peroxidation and the progression of metabolic dysfunction, highlighting their potential as diagnostic biomarkers and therapeutic targets for glucolipid metabolic disorders. Discussion: The available evidence indicates that oxylipins exert both protective and detrimental effects, depending on their biosynthetic origin, fatty acid precursor and receptor specificity. Although considerable progress has been made in elucidating oxylipin-mediated metabolic signaling, variations in experimental models, analytical methodologies and clinical populations continue to limit the translation of these findings into therapeutic applications. Future studies integrating standardized lipidomic profiling with mechanistic investigations and well-designed clinical studies are essential to validate oxylipin-based biomarkers, establish causal relationships and facilitate the development of targeted therapeutic strategies for glucolipid metabolic disorders. Conclusion: Oxylipins are key regulators of hepatic glucolipid metabolism, linking dietary lipid metabolism with oxidative stress, inflammatory signaling and insulin sensitivity. Their diverse biological functions and context-dependent effects underscore their potential as diagnostic biomarkers and therapeutic targets for MASLD, insulin resistance, type 2 diabetes mellitus, obesity and other glucolipid metabolic disorders.
- 28 August 2026
- Published by Bentham Science Publishers Ltd. in Glucolipid Metabolic Disorders
- Vol. 01  (1) , 75-91
From Soybean Oil to Signaling Molecules: Oxylipins as Pharmacologically Active Lipids Modulating Liver and Metabolic Health
Introduction: Glucolipid metabolic disorders, including Metabolic Dysfunction- Associated Steatotic Liver Disease (MASLD), formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD), insulin resistance, Type 2 Diabetes Mellitus (T2DM) and obesity, are characterized by dysregulated hepatic lipid metabolism, impaired glucose homeostasis and systemic energy imbalance. Oxylipins, a diverse class of oxygenated bioactive metabolites derived from Polyunsaturated Fatty Acids (PUFAs), have emerged as key lipid mediators that link dietary fatty acid composition to intracellular metabolic signaling pathways. Soybean oil, a major dietary source of linoleic acid and α-linolenic acid, provides abundant substrates for oxylipin biosynthesis via cyclooxygenase (COX), lipoxygenase (LOX), cytochrome P450 (CYP), and non-enzymatic oxidative pathways. This review comprehensively examines the mechanistic roles of soybean oil-derived oxylipins in regulating hepatic glucolipid metabolism and highlights their potential as therapeutic targets and diagnostic biomarkers for glucolipid metabolic disorders. Methods: Relevant peer-reviewed studies were identified through a comprehensive review of experimental, clinical, and lipidomics-based literature. Evidence related to oxylipin biosynthesis, receptormediated signaling, metabolic regulation, oxidative stress, inflammation, and glucolipid metabolic disorders was critically evaluated and systematically synthesized to provide an integrated mechanistic framework and highlight the therapeutic and diagnostic potential of oxylipins in metabolic diseases. Results: Current evidence indicates that oxylipins play pivotal roles in regulating glucolipid metabolism by activating G protein-coupled receptors and nuclear receptors, including Peroxisome Proliferator- Activated Receptor-α (PPARα), Peroxisome Proliferator-Activated Receptor-γ (PPARγ) and Liver X Receptors (LXRs). Through these signaling pathways, oxylipins regulate fatty acid oxidation, de novo lipogenesis, gluconeogenesis and insulin signaling, thereby maintaining metabolic homeostasis. Linoleic acid-derived oxylipins are generally associated with enhanced oxidative stress, mitochondrial dysfunction, chronic inflammation and insulin resistance. In contrast, cytochrome P450 (CYP)-derived epoxy-fatty acids exhibit anti-inflammatory, antioxidant and insulin-sensitizing properties that promote hepatic metabolic homeostasis. Moreover, disease-specific alterations in oxylipin profiles are strongly associated with hepatic lipid accumulation, lipid peroxidation and the progression of metabolic dysfunction, highlighting their potential as diagnostic biomarkers and therapeutic targets for glucolipid metabolic disorders. Discussion: The available evidence indicates that oxylipins exert both protective and detrimental effects, depending on their biosynthetic origin, fatty acid precursor and receptor specificity. Although considerable progress has been made in elucidating oxylipin-mediated metabolic signaling, variations in experimental models, analytical methodologies and clinical populations continue to limit the translation of these findings into therapeutic applications. Future studies integrating standardized lipidomic profiling with mechanistic investigations and well-designed clinical studies are essential to validate oxylipin-based biomarkers, establish causal relationships and facilitate the development of targeted therapeutic strategies for glucolipid metabolic disorders. Conclusion: Oxylipins are key regulators of hepatic glucolipid metabolism, linking dietary lipid metabolism with oxidative stress, inflammatory signaling and insulin sensitivity. Their diverse biological functions and context-dependent effects underscore their potential as diagnostic biomarkers and therapeutic targets for MASLD, insulin resistance, type 2 diabetes mellitus, obesity and other glucolipid metabolic disorders.
- Open Access
- 29 July 2026
- Published by Elsevier in The Veterinary Journal: Pharmacology & Toxicology
- Vol. 1  (3)
Advanced human-relevant in vitro and in silico toxicology approaches as alternatives to animal testing
- 29 July 2026
- Published by Elsevier in The Veterinary Journal: Pharmacology & Toxicology
- Vol. 1  (3)
Open AccessAdvanced human-relevant in vitro and in silico toxicology approaches as alternatives to animal testing
- 30 June 2026
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 35  (1) , 84
Hepatoprotective effects of diosgenin and gallic acid against chemical-induced liver injury in rats
- 30 June 2026
- Published by Springer Nature in Comparative Clinical Pathology
- Vol. 35  (1) , 84
Hepatoprotective effects of diosgenin and gallic acid against chemical-induced liver injury in rats